We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Dyno

News List

Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement contractpharma
December 03, 2021
Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.
Astellas and Dyno Therapeutics to Collaborate on Research to Develop Next-Gen AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle AmericanPharmaceuticalReview
December 03, 2021
Astellas Pharma Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
Astellas and Dyno Therapeutics to develop AAV gene therapy vectors Pharmaceutical-Technology
December 03, 2021
Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B contractpharma
October 16, 2020
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.